Excited to share the 1st preprint from our incredible team at Interdict Bio as we progress novel, small-molecule sequence-selective inhibitors of translation toward the clinic to address difficult to treat cancers! #ribosome #interdictor
Check out the preprint here: www.biorxiv.org/content/10.1...
Anthony Schuller
This one is mostly about the title subject (featuring a very interesting compound from academia) but it’s also about attacking the NIH:
Incredibly proud of our small but mighty team at Interdict Bio as we bring the interdictor modality closer to the clinic! Check out our first publication that lays the foundation for context-dependent translation modulators as a therapeutic approach for cancer!
www.nature.com/articles/s41...
Robust protein synthesis by the ribosome is required for rapid cancer growth. Here authors present interdictors, small molecule inhibitors of protein synthesis with context-dependent activity that inh...
Selective translational stalling is coming of age...
doi.org/10.1101/2025...
"On a molecular level, our structural studies reveal that interdictors bind in a linkerless heterobifunctional manner to both the rRNA and the nascent peptide chain ... much the way a PROTAC can be modularly designed and constructed"
Inhibitors of protein synthesis, including anisomycin, homoharringtonine, and other natural products bind in the peptidyl-transferase center (PTC) of the eukaryotic ribosome to inhibit translation. Re...
Inhibitors of protein synthesis, including anisomycin, homoharringtonine, and other natural products bind in the peptidyl-transferase center (PTC) of the eukaryotic ribosome to inhibit translation. Re...
